Shares of Quanterix Corp. (QTRX), a company focused on using technology to improve biomarker analysis and advance precision health, are up over 15% at $6.79 in premarket trading Monday, on no specific news.
Earlier this year, the company agreed to acquire Akoya Biosciences (AKYA) in an all-stock transaction. The transaction, which is scheduled to close in the second quarter of 2025, is expected to generate $40 million in annual cost synergies by the end of 2026, with a path to positive free cash flow generation in 2026. The deal is subject to certain closing conditions, including approval by both companies' shareholders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com